There are 108 resources available
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Presenter: Li Zhang
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1259O - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)
Presenter: Yukihiro Toi
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA41 - LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Presenter: Zarnie Lwin
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1019O - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Nehal Lakhani
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Why do we need phase I clinical trials?
Presenter: Martijn Lolkema
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Slides
Webcast
From referral for to participation in phase I clinical trials: Patient journeys and preliminary results in the development of an online value clarification tool
Presenter: Liza Van Lent
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Slides
Webcast
Q&A live discussion
Presenter: Ruben Martin Payo
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Webcast
Q&A and live discussion
Presenter: Silvia Formenti
Session: Proffered Paper - Investigational immunotherapy
Resources:
Webcast
Invited Discussant 1020O and 1021O
Presenter: Maria Rescigno
Session: Proffered Paper - Investigational immunotherapy
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Silvia Formenti
Session: Proffered Paper - Investigational immunotherapy
Resources:
Webcast